Maria J. Ribal

Head of Uro-Oncology Unit. @hospitalclinic. Chair of #eauguidelines Office In love with Urology!! Passion for life!!!

[Maria J. Ribal @MariaJRibal]

No words ... simply touching #jaumeplensa

[Maria J. Ribal @MariaJRibal]

@albasierrad Moltes felicitats Doctora Sierra. Molt
Ben fet..!!

[Maria J. Ribal @MariaJRibal]

@PabloNContreras @AUrologica @SauUrologia @CAU_URO @ResidentesCAU @ResidentesAEU @AmerUrological @Uroweb @SIU_urology @EAU_YAUroTech @InfoAeu @SIU_Italia @so_uro Un placer vernos como siempre..

[Arturo Domínguez @ADominguez_Uro]

Gran iniciativa de la @scurologia amb una taula multidisciplinària sobre el tractament del tumor de bufeta en diferents escenaris.

Necessitem més espais de debat com aquest per avançar junts.

@MariaJRibal @RodriguezFaba @dr_flozano @mercaderclaudia @Feltes81 @terebonfill

[ChristianRadmayr @radmayr]

The new multistakeholder #guidelines emphasize the need for #multidisciplinary care lifelong. Download the @ESPUorg @Uroweb @ifsbh @ERNIthaca @ERN_eUROGEN @ernerknet guidelines for free. Go to https://t.co/RT7EWQiHcY or read the summary paper https://t.co/RprpKBicCh

[Maria J. Ribal @MariaJRibal]

@DrChoueiri @myESMO @Annals_Oncology @g_develasco @drenriquegrande @ESMO_Open @Tony_Calles @cdanicas So sad, really sad.

[Maria J. Ribal @MariaJRibal]

@scserendipity1 Ohhh!!! Thank you for you words..!!!

[Maria J. Ribal @MariaJRibal]

What a few weeks it’s been… and what’s still to come! 😅☕ #ilooklikeaurologist #eauguidelines

[Syed A Hussain @ProfSyedHussain]

It was great to see you all and catch up. Keep driving the field forward.Thanks @myESMO @PGrivasMDPhD @RebeccaDSing @dmukherji @DrChoueiri @g_develasco @MariaJRibal @brittsuelmann @nachoduranm @drenriquegrande @tompowles1 @YigeBao @mdesantis234 @cdanicas @docjavip @dralvaropinto

[Maria J. Ribal @MariaJRibal]

@scserendipity1 @shilpaonc @OpenMedInsights @OpenMedKate @montypal @DrSapnaPatel @DrShubhamPant We didn’t meet at the end..! All my best..!!!🙏🏻🙏🏻😍😍

[NEJM @NEJM]

Presented at #ESMO26:

In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1% with surgery alone. Full phase 3 VOLGA trial results: https://t.co/9Eyzy0GnQq

@myESMO

[Yüksel Ürün @DrYukselUrun]

Hundreds of posters. Thousands of hours of research.

Different questions. The same passion.

More effective treatments. Fairer cancer care. For every patient, everywhere.

@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @urologysummit

[Syed A Hussain @ProfSyedHussain]

It was my pleasure & privilege to be part of the ESMO 2026 faculty. Enjoyed role to co-chair the session @MariaJRibal & @BrittSuelmann Great abstracts & presentations. @Mariadesantis @Andreanecchi @MattGalsky @MyEsmo Enjoyed discussing exciting abstracts#NIAGARA #GDFATHER -Neo

[Tom Powles @tompowles1]

VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.

[Tom Powles @tompowles1]

ctDNA analysis is an increasingly utilised prognostic tool in muscle invasive bladder cancer. In VOLGA 78% of the muscle invasive bladder cancer patients were ctDNA positive at baseline which was prognostic. Also, the combination of perioperative durvalumab and neoadjuvant EV cleared ctDNA in 60% of patients (using the Natera Genome assay which has increased sensitivity). Clearance was associated with much better outcomes. #ESMO26

[Tom Powles @tompowles1]

VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert

[Maria J. Ribal @MariaJRibal]

@WenchangYue 🙏🏻🙏🏻

[Maria J. Ribal @MariaJRibal]

Great discussions at #ESMO2026!

A pleasure to participate as an invited discussant in today’s Rapid Oral session on #BladderCancer.

From NMIBC to metastatic disease: ADCs, immunotherapy, biomarkers and patient-reported outcomes. The therapeutic landscape is changing rapidly!

But presenting new evidence is only part of the story. Putting results into context and critically assessing their clinical value is essential to understand what should change in daily practice.

Great to share the session with Britt Suelmann and @ProfSyedHussain.

Thank you @myESMO for the invitation and to all the investigators for their outstanding research! And above all : thank you to our patients for their trust.!

#UroOncology #GUOncology

[Niklas Klümper @niklas_kluemper]

🚨 VOLGA is positive! But how much perioperative EV do we really need in MIBC?

Interesting comparison with KEYNOTE-905 at #ESMO26:

🔹 VOLGA (EV + durvalumab): 2-year EFS 64%, OS 78%, pCR 45%. EFS HR 0.51.

🔹 KEYNOTE-905 (EV + pembrolizumab): 2-year EFS 74.7%, OS 79.7%, pCR 57.1%. EFS HR 0.40.

Numerically lower EFS and pCR in VOLGA. Why?

Different patient populations and tumor characteristics? Different study designs? It seems premature to attribute these differences to pembrolizumab vs durvalumab.

But the most intriguing question is how much benefit does adjuvant EV actually add?

VOLGA achieved a significant OS benefit with just 3 neoadjuvant EV cycles and NO adjuvant EV, whereas KEYNOTE-905 planned 9 EV cycles (3 neoadjuvant + 6 adjuvant)—and fewer than half of patients reportedly completed the full planned EV course.

Could pCR and ctDNA clearance help us safely omit adjuvant EV and reduce cumulative toxicity?

⚠️ Cross-trial comparisons are hypothesis-generating, not evidence of superiority or equivalence. Only prospective trials can establish the incremental benefit of adjuvant EV.

More EV ≠ necessarily better outcomes. Let’s identify who really needs it! 🔬

@OncoAlert @weoncologists @tompowles1 @urotoday @Uromigos

@OncoAlert Faculty @DrChoueiri , @tompowles1 , @apolo_andrea , @neerajaiims , @montypal , @Silke_Gillessen , @AOmlin , @brian_rini , @PGrivasMDPhD , @TiansterZhang , @amerseburger , @DrDanielHeng , @HHammersMD , @scocmem , @AndreaNecchi , @AmandaNizamMD , @drenriquegrande , @nataliagandur , @AlbigesL , @cdanicas , @declangmurphy , @seanmmcbride , @shilpaonc , @DrRanaMcKay , @scserendipity1 , @DrYukselUrun , @ravikanesvaran , @BraunMDPhD , @EfstathiouEleni , @mzugman , @crisbergerot @Markuseckstein3

[UroToday.com @urotoday]

KEYNOTE-B15 ctDNA Analysis: Perioperative Enfortumab Vedotin + Pembrolizumab in Cisplatin-Eligible #MIBC. Presented by Jonathan Chatzkel, MD @MoffittNews. #ESMO26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/WCCuF4jwoA #BladderCancer #PrecisionOncology @myESMO